Rationale and Methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF)
Conclusions Results from the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF) will help establish a mechanistic understanding of ARNI therapeutic benefits and provide clinicians with clarity on how to interpret information on biomarkers during treatment (PROVE-HF ClinicalTrials.gov identifier: NCT02887183). Graphical abstract
Source: American Heart Journal - Category: Cardiology Source Type: research
More News: Cardiology | Cardiomyopathy | Cardiovascular | Diovan | Heart | Heart Failure | Study | USA Health